Horrible asian OGG1 mutant issues

#1

compound 38 is not an OGG1 inhibitor. It is a newer OGG1 activator, specifically a serotonin-derived ORCA that accele
rates the AP-lyase step of OGG1-mediated repair. In the 2025 paper, it was optimized to very high potency (AC50 0.040
μM) and the authors explicitly say it “accelerated the AP-lyase activity of the disease-associated mutant Ser326Cys.”
They also model it in the DNA-bound context, which matches the way you asked to run Boltz. Sources: J Med Chem 2025 /
PMC12621200 (Giving an Enzyme Scissors: Serotonin Derivatives as Potent Organocatalytic Switches for DNA Repair Enzyme OGG1 - PMC) and the older OGG1 activator review summary RSC Med
Chem 2024 / PMC11487406 (Therapeutic upregulation of DNA repair pathways: strategies and small molecule activators - PMC).

What that means for your result:

  • Our Boltz panel puts compound 38 first in the S326C + 8-oxoG:C context: C:/Users/User.codex/
    alex_chen_nucleus_dna_download_vcf_NU-PGIK-3398%20(1).vcf/gene_sequences/boltz2_ogg1/results/
    boltz2_ogg1_dna_panel_metrics.tsv
  • But Boltz does not prove “restores mutant to WT.”
  • The literature-backed claim for compound 38 is narrower: it improves Ser326Cys AP-lyase activity.
  • If you want the stronger “back toward WT” precedent, that is actually compound F: in the 2018 Ser326Cys study, the
    authors say compound F restored variant 8-oxodG incision activity to wild-type extract levels in their mitochondrial
    system. Source: Free Radic Biol Med 2018 / PMC6098717 (Enhanced Mitochondrial DNA Repair of the Common Disease- Associated Variant, Ser326Cys, of hOGG1 through Small Molecule Intervention - PMC).

So the honest ranking is:

  • compound 38: best current first-pass candidate from your Boltz run, and real literature support for Ser326Cys
    activation
  • compound F: older scaffold, but the cleanest published “restored to WT-like activity” evidence in a Ser326Cys model
  • TH10785: strong activator scaffold overall, but more “gain a new function” than “specifically rescue Ser326Cys to
    WT”

On upregulating OGG1: yes, in principle that could partly compensate, but not in a simple linear way.

So my blunt take:

  • compound 38 looks like a plausible rescue-style activator.
  • No, we cannot say from Boltz that it restores your mutant to true WT function.
  • Yes, boosting OGG1 activity/expression is a plausible compensation strategy, but it should be treated as partial
    rescue, not a full correction.

If you want, I can do the next two useful steps:

  1. run matched WT + 8-oxoG:C + compound 38 / compound F controls so we can compare mutant vs WT directly;
  2. build a short ranked “OGG1 compensation” note covering compound 38, compound F, TH10785, CoQ10/ubiquinol, and
    SIRT3/AMPK/HDAC1 routes.
#2

• Yes, but mostly as an indirect support strategy, not a clean substitute for compound 38.

My read is:

The upstream biology that matters most is:

So the practical phytochemical hierarchy is:

  1. Resveratrol
  2. Sulforaphane
  3. maybe Curcumin as a low-confidence general oxidative-stress support compound, not an OGG1-specific tool

Important caveat:

For your Ser326Cys context, the cleanest summary is:

  • phytochemicals can plausibly support the axis
  • they are much more likely to be partial compensation than true normalization to wild type
  • resveratrol and sulforaphane are the two I would take most seriously

If you want, I can do a Boltz follow-up next with a small exploratory panel:

  • OGG1 S326C + 8-oxoG:C + resveratrol
  • OGG1 S326C + 8-oxoG:C + sulforaphane
  • OGG1 S326C + 8-oxoG:C + curcumin
  • plus WT controls for the top 1-2 so we can compare directionally.
#3

If you exclude resveratrol, the best remaining options are not equally good.

My ranking for your OGG1 Ser326Cys context is:

So the practical takeaway is:

  • best plant-derived OGG1 support candidate: sulforaphane
  • best accessible non-prescription OGG1-support candidate overall: ubiquinol
  • curcumin and EGCG are much weaker, more generic antioxidant plays

One caution that matters: more OGG1 is not automatically a pure win. Recent reviews emphasize that OGG1 has both repa
ir and signaling/inflammatory roles, so indiscriminate upregulation is not universally beneficial: PMID 39119702
(OGG1: An emerging multifunctional therapeutic target for the treatment of diseases caused by oxidative DNA damage - PubMed), PMC11487406 (Therapeutic upregulation of DNA repair pathways: strategies and small molecule activators - PMC)

If you want, I can do one focused next pass on:

  • sulforaphane
  • ubiquinol
  • NRF2
  • SIRT3
  • AMPK